On Monday, Summit Therapeutics Inc (SMMT) stock saw a modest uptick, ending the day at $21.77 which represents a slight increase of $0.36 or 1.68% from the prior close of $21.41. The stock opened at ...

To say this has been a big year for Summit Therapeutics (NASDAQ: SMMT) would be a huge understatement. The stock has risen ...

This year, Summit Therapeutics Inc. (SMMT) leads the parade of winners among large stocks (those with a market value of $10 ...

Now this is a fine way to begin a week on the stock market. Summit Therapeutics (NASDAQ: SMMT) saw its stock price rise ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

On Thursday, Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $18.59 which represents a decrease of $-0.06 or -0.32% from the prior close of $18.65. The stock opened at $18.75 and ...

JMP Securities initiated coverage of Summit Therapeutics (SMMT) with an Outperform rating and $32 price target The firm acknowledges the risk associated with data obtained from Chinese patients only, ...

Summit Therapeutics Inc's innovative approach to combating serious infectious diseases positions it as a potential leader in ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

HUNTSVILLE, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American ... Serina presented a case study at the 14th Annual Injectables Summit in Boston, MA, detailing the ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, today highlighted a key opinion leader presen ...